At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
NST-1024drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label Study to Evaluate the Effects of NST-1024 on the Pharmacokinetics of Caffeine, Flurbiprofen, Omeprazole, Metoprolol, and Midazolam in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating NST-1024 for Healthy Volunteers. Completed, enrolled 24 participants across 1 site.
Detailed Summary
Phase 1, open label study to evaluate the effects of NST-1024 on the pharmacokinetics (PK) of caffeine (and paraxanthine), flurbiprofen, omeprazole, metoprolol, and midazolam (and 1-hydroxymidazolam) in healthy male and female subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedMay 2022
Enrollment StartJul 2022
Primary CompletionSep 2022
TodayJul 2026
First PostedMay 10, 2022
Enrollment StartJul 19, 2022
Primary CompletionSep 7, 2022
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.1 years ago
Interventions
NST-1024drug
Drug Drug interactions between NST-1024 and caffeine (and paraxanthine), flurbiprofen, omeprazole, metoprolol, and midazolam